Lyell Immunopharma Inc (LYEL): Congress and insider trades

Who in Congress and inside the company traded LYEL, when each filing appeared, and what buying after each one would have earned against the S&P 500.

Key Facts

  • Lyell Immunopharma Inc (LYEL) is a listed stock on NASDAQ.
  • Insiders filed 0 open market buys worth $0 and 8 sells worth $47.2K, the latest filed 2026-09-10 (10 September 2026).
  • Data as of 2026-09-29 (29 September 2026).
Congress buys 0 0 members
Congress sells 0
Insider buys 0 $0
Insider sells 8 $47.2K
Congress buys vs S&P, 90d n/a 0 scored buys
Insider buys vs S&P, 90d n/a 0 scored buys

Insider trades in LYEL

as of 2026-09-10
Open market insider trades in LYEL, newest first.
FiledInsiderTypeSharesPriceValue90 day vs S&P
10 Sep 2026 Shook David sell 500 $12.70 $6.3K n/a
20 Jul 2026 Innovative Cellular Therapeuti sell 10 $13.70 $137 n/a
17 Jul 2026 Innovative Cellular Therapeuti sell 10 $13.73 $137 n/a
15 Jun 2026 Seely Lynn sell 388 $18.91 $7.3K n/a
15 Jun 2026 Hill Stephen J. sell 89 $18.92 $1.7K n/a
15 Jun 2026 Bulis Veronica Sanchez sell 217 $18.91 $4.1K n/a
15 Jun 2026 Lee Gary K. sell 130 $18.92 $2.5K n/a
11 Jun 2026 Shook David sell 1,977 $12.64 $25.0K n/a

Frequently asked questions

Who has bought LYEL?

0 Congress buys by 0 members and 0 insider buys are on file. The tables on this page list every one.

Did buying LYEL after a disclosure beat the market?

No disclosed buy of this stock has matured 90 days yet. A single stock is a small sample.

Sources: Congressional trades: STOCK Act disclosures, collected from CapitolTrades. Insider trades: SEC Form 4 filings, collected from Finviz. Prices: Yahoo Finance daily adjusted closes. Data as of 2026-09-29 (29 September 2026). About these sources.

Not investment advice. Past disclosed trades do not predict future returns. Disclosures are published late, so the trades shown are ones you could only have copied after the fact. Talk to a licensed adviser before you invest.